{"slug":"semax-chemo-neuropathy","verification":{"valid":true,"entries":1,"head":"fc56761da4a26a915f953247ac098c041240f29571d8d924dbaf95d5fe92c064"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.025226,"waste_cost_usd":0,"total_tokens":17121,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.025226,"tokens_total":17121,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:14:54.157Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Semax for Chemotherapy-Induced Neuropathy: Evidence Review","register":"source_ledger","body":"## What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)\n\nChemotherapy-induced peripheral neuropathy develops when certain chemo agents damage peripheral nerves. Platinum drugs, taxanes, and vinca alkaloids commonly trigger this. Sensory axons in a stocking-glove distribution degenerate first. Axonal transport slows. Mitochondrial function in neurons drops. Inflammatory signals rise around the nerves. Pain, tingling, numbness, and balance problems follow. The process is degenerative: damage outpaces the nerves' natural repair capacity. Some symptoms improve after chemo ends, but many persist for months or years because repair pathways stay under-activated.\n\nBDNF supports neuron survival, axon maintenance, and synaptic repair. Levels can fall during chemo stress and recovery. If your CIPN includes slowed nerve regeneration or lingering sensory deficits, that layer of breakdown matters for any discussion of repair-focused compounds.\n\n## Why Semax might help you\n\n1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\n2. **What keeps failing:** BDNF decline, nerve stress from chemo agents, slowed axon repair and sensory signaling after treatment.\n3. **What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\n4. **Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\n\nSemax has been examined mainly in stroke and optic-nerve contexts for its effects on BDNF expression. If your CIPN involves reduced neurotrophic support, the peptide's studied actions on BDNF transcription and neuron survival pathways align with repair rather than symptom suppression.\n\n## Why Gabapentin / pregabalin matters for you\n\n**Drug:** Gabapentin / pregabalin\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\n**Therefore for you:** This drug suppresses a signal. It can reduce pain intensity and improve daily function while nerves remain damaged. That helps quality of life but does not address the underlying axonal degeneration or support regeneration. Using it trades ongoing symptom control for time during which repair pathways would need separate activation.\n\n## How these fit together\n\nSingle-compound focus — Semax targets the neural / cognitive repair layer. Gabapentin / pregabalin addresses symptom load through signal suppression. They operate on different parts of the problem: one studied for potential support of BDNF-driven repair, the other for immediate pain gating. No overlap in mechanism means they could be considered together only if both layers need attention, without one replacing the other.\n\n## What the evidence actually shows\n\nNo human trials test Semax specifically in chemotherapy-induced peripheral neuropathy (preclinical/mechanistic). Semax increases BDNF mRNA and protein in rat hippocampus and cortex after ischemia models (preclinical). One small human study in ischemic stroke patients found Semax raised plasma BDNF and improved motor scores when added to rehabilitation (human). Semax showed neuroprotective effects in rat optic-nerve models and one small open-label human series on glaucomatous optic neuropathy (preclinical + human, small). Commercial sites mention possible benefit in non-proliferative diabetic neuropathy without published trial data (anecdotal/mechanistic).\n\nCIPN itself has large observational data: prevalence reaches 68 % at one month post-chemo, falling to 30 % at six months (human epidemiology). No Semax data exist in that population.\n\n## What scientists say\n\nResearchers describe Semax as an ACTH(4-10) analog that modulates neurotrophin expression. Animal work links it to faster BDNF induction after hypoxic or ischemic stress. Human stroke rehabilitation data remain limited to Russian-language reports. No peer-reviewed CIPN-specific conclusions appear in Western literature.\n\n## What people say on Reddit\n\nOne user with small-fiber neuropathy reported trying Semax nasal spray and noting subjective sensory changes on the first night (anecdotal). Broader nootropics threads discuss Semax for cognitive or post-concussion use but contain no CIPN reports. Hair-shedding anecdotes appear in unrelated contexts.\n\n## What people say on X\n\nPublic posts mentioning Semax and neuropathy remain absent in searched results. Discussions center on stroke recovery or general nootropic use.\n\n## What we do not know\n\nDirect effects of Semax on CIPN symptoms, nerve conduction, or axon regrowth in humans are unknown. Dose, duration, and timing relative to chemo have not been studied. Long-term safety in cancer survivors is unreported. Whether BDNF elevation translates to functional nerve repair after chemo damage remains speculative.\n\n## Safety and limits\n\nSemax is approved in Russia for certain neurological conditions but lacks FDA evaluation for CIPN or any neuropathy. Reported side effects in available data are minimal. Any use occurs outside regulated medical channels. Evidence grading shows heavy reliance on preclinical BDNF work and very small human stroke or optic-nerve series. Larger controlled trials do not exist for this indication.","claims":[{"id":"c1","text":"No published human trials examine Semax in chemotherapy-induced peripheral neuropathy.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["web:0","web:1"],"source_status":"sourced","why_material":"Establishes the evidence gap for this specific condition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:14:53.792Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Semax increases BDNF mRNA and protein expression in rat brain after ischemia models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["web:19"],"source_status":"sourced","why_material":"Supports the mechanistic link to neural repair pathways.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:14:53.792Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"A small human study found Semax raised plasma BDNF and improved motor outcomes in ischemic stroke patients during rehabilitation.","section":"What the evidence actually shows","tier":"human","source_ids":["web:27"],"source_status":"sourced","why_material":"Provides the only direct human BDNF data for Semax.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:14:53.792Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"CIPN prevalence reaches 68% one month after neurotoxic chemotherapy and declines to 30% by six months.","section":"What the evidence actually shows","tier":"human","source_ids":["web:1"],"source_status":"sourced","why_material":"Quantifies the scale of the condition independent of any compound.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:14:53.792Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"One Reddit user with small-fiber neuropathy reported subjective sensory changes after first use of Semax nasal spray.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["web:9"],"source_status":"sourced","why_material":"Documents the only publicly available user report linking Semax to neuropathy symptoms.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:14:53.792Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"web:0","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5656281/","title":"Chemotherapy-Induced Peripheral Neuropathy - PMC - NIH","quote":"Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer.","link_status":"ok","quote_status":"verified"},{"id":"web:1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11674975/","title":"Chemotherapy-Induced Peripheral Neuropathy: Assessment ...","quote":"Seretny et al. (2014) conducted a large systematic review with 4,179 patients and found that the prevalence of CIPN after chemotherapy was 68% at one month, 60% at three months, and 30% at six months.","link_status":"ok","quote_status":"unverified"},{"id":"web:19","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11498467/","title":"Semax and Pro-Gly-Pro Activate the Transcription of ...","quote":"It has been suggested that the neuroprotective effects of Semax are related to neurotrophin gene expression: the rapid induction of Bdnf and Ngf mRNAs in rat ...","link_status":"ok","quote_status":"unverified"},{"id":"web:27","type":"other","url":"https://www.researchgate.net/publication/325375504_The_efficacy_of_semax_in_the_tretament_of_patients_at_different_stages_of_ischemic_stroke","title":"The efficacy of semax in the tretament of patients at different stages of ischemic stroke","quote":"Administration of semax and high BDNF levels accelerated the improvement and ameliorated the final outcome of Barthel score index.","link_status":"http_403","quote_status":"unverified"},{"id":"web:9","type":"reddit","url":"https://www.reddit.com/r/smallfiberneuropathy/comments/1ds2bl5/semax/","title":"Semax : r/smallfiberneuropathy","quote":"I decided to try a nootropic nasal spray called Semax (peptide based) which is a russian stroke treatment. At night on the day I first started using it I ...","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":14061,"tokens_out":3060,"cost":0.02522625,"prev_hash":"genesis","hash":"fc56761da4a26a915f953247ac098c041240f29571d8d924dbaf95d5fe92c064"}]}